Collegium Pharmaceutical (COLL) News Today $30.90 +0.18 (+0.59%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Indivior CFO steps down from board after discussions with Oaktree CapitalDecember 17 at 4:39 PM | msn.comWellington Management Group LLP Increases Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Wellington Management Group LLP raised its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 17.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 114,640 shares of the specialty pDecember 17 at 3:43 AM | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock Holdings Lifted by Fmr LLCFmr LLC raised its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 1,532.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 37,752 shares of the specialty pharmaceutical company's stock after buying an additDecember 16 at 3:21 AM | marketbeat.comJanus Henderson Group PLC Buys 55,572 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Janus Henderson Group PLC increased its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 399.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 69,485 shares of the specialty pharmaceutical company's stock afterDecember 12, 2024 | marketbeat.comLoomis Sayles & Co. L P Has $737,000 Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Loomis Sayles & Co. L P lessened its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 90.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,075 shares of the specialty pharmaceuticalNovember 28, 2024 | marketbeat.comPenserra Capital Management LLC Invests $757,000 in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Penserra Capital Management LLC purchased a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 19,600 shares of the specialty pharmaceuticaNovember 28, 2024 | marketbeat.comRubric Capital Management LP Lowers Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Rubric Capital Management LP trimmed its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 46.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,250,000 shares of thNovember 27, 2024 | marketbeat.comCollegium Pharmaceutical: Strong Growth With Pain Management And ADHD ExpansionNovember 26, 2024 | seekingalpha.comMassachusetts Financial Services Co. MA Boosts Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Massachusetts Financial Services Co. MA grew its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 17.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 765,692 shares of the specialty pharNovember 26, 2024 | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five research firms that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and thNovember 24, 2024 | marketbeat.comPacer Advisors Inc. Trims Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Pacer Advisors Inc. cut its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 24.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,589,648 shares of the specialty pharmaceutical compNovember 22, 2024 | marketbeat.com121,446 Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Bought by Empowered Funds LLCEmpowered Funds LLC bought a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 121,446 shares of the specialty pharmaceuticNovember 18, 2024 | marketbeat.comVictory Capital Management Inc. Has $27.46 Million Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Victory Capital Management Inc. grew its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 43.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 710,688 shares of the specialty pharmaceutical company'sNovember 18, 2024 | marketbeat.comCollegium Pharmaceutical's (NASDAQ:COLL) Performance Is Even Better Than Its Earnings SuggestNovember 14, 2024 | finance.yahoo.comKnight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)November 14, 2024 | globenewswire.comCollegium to Participate in Upcoming Investor ConferencesNovember 13, 2024 | finance.yahoo.comMeritage Portfolio Management Purchases Shares of 19,776 Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Meritage Portfolio Management bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 19,776 shares of the specialty pharmaceutical company's stock, valuedNovember 11, 2024 | marketbeat.comPrincipal Financial Group Inc. Buys 64,958 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Principal Financial Group Inc. increased its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 3.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,745,818 shares of the specialty pharmaceutical comNovember 10, 2024 | marketbeat.comCollegium Pharmaceutical Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsNovember 9, 2024 | finance.yahoo.comCollegium Pharmaceutical: Hold Rating Amid Uncertainty Despite Strong Q3 PerformanceNovember 9, 2024 | markets.businessinsider.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | msn.comRobeco Institutional Asset Management B.V. Has $4.44 Million Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Robeco Institutional Asset Management B.V. boosted its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 265.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 114,965 shares of the specialty phaNovember 9, 2024 | marketbeat.comCollegium Pharmaceutical Reports Strong Q3 2024 ResultsNovember 8, 2024 | markets.businessinsider.comCollegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | seekingalpha.comCollegium Pharmaceutical appoints Vikram Karnani as CEONovember 8, 2024 | markets.businessinsider.comCollegium Pharmaceutical, Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 7, 2024 | seekingalpha.comPiper Sandler Remains a Hold on Pacira Pharmaceuticals (PCRX)November 7, 2024 | markets.businessinsider.comCollegium Pharmaceutical Taps Vikram Karnani as CEONovember 7, 2024 | marketwatch.comCollegium Appoints Vikram Karnani as Chief Executive OfficerNovember 7, 2024 | markets.businessinsider.comCollegium Reports Record Third Quarter 2024 Financial ResultsNovember 7, 2024 | globenewswire.comCollegium Pharmaceutical (NASDAQ:COLL) Stock Quotes, Forecast and News SummaryNovember 7, 2024 | benzinga.comA Preview Of Collegium Pharmaceutical's EarningsNovember 6, 2024 | benzinga.comWhat To Expect From Collegium Pharmaceutical Inc (COLL) Q3 2024 EarningsNovember 6, 2024 | finance.yahoo.comEmerald Advisers LLC Boosts Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Emerald Advisers LLC boosted its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 27.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 827,302 shares of the specialtNovember 3, 2024 | marketbeat.comCollegium Pharmaceutical (COLL) to Release Quarterly Earnings on ThursdayCollegium Pharmaceutical (NASDAQ:COLL) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=639719)October 31, 2024 | marketbeat.comCollegium Pharmaceutical (COLL) Receives a Buy from Truist FinancialOctober 30, 2024 | markets.businessinsider.comAllspring Global Investments Holdings LLC Purchases 36,331 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Allspring Global Investments Holdings LLC grew its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 83.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 79,822 shares of the specialty phaOctober 30, 2024 | marketbeat.comAssenagon Asset Management S.A. Sells 188,423 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Assenagon Asset Management S.A. lessened its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 52.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 173,714 shares of the specialty pharmaceutical companOctober 29, 2024 | marketbeat.comStockNews.com Downgrades Collegium Pharmaceutical (NASDAQ:COLL) to BuyStockNews.com cut shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Wednesday.October 23, 2024 | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Inspire Investing LLCInspire Investing LLC lessened its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 64.5% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,813 shares of the specialty pharmaceutical company's stockOctober 19, 2024 | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Short Interest Down 6.5% in SeptemberCollegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) was the recipient of a large decline in short interest in the month of September. As of September 30th, there was short interest totalling 5,940,000 shares, a decline of 6.5% from the September 15th total of 6,350,000 shares. Currently, 19.0% of the company's shares are short sold. Based on an average daily volume of 432,200 shares, the short-interest ratio is presently 13.7 days.October 16, 2024 | marketbeat.comSanctuary Advisors LLC Makes New Investment in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Sanctuary Advisors LLC bought a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 16,245 shares of the specialty pharmaceuticalOctober 16, 2024 | marketbeat.comCollegium Pharmaceutical (NASDAQ:COLL) Rating Increased to Strong-Buy at StockNews.comStockNews.com upgraded Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Tuesday.October 15, 2024 | marketbeat.comCollegium Pharmaceutical (COLL) Receives a Hold from Piper SandlerOctober 11, 2024 | markets.businessinsider.comCollegium Pharmaceutical (NASDAQ:COLL) Given "Neutral" Rating at Piper SandlerPiper Sandler reaffirmed a "neutral" rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a research report on Friday.October 11, 2024 | marketbeat.comCollegium Pharmaceutical Inc (COLL) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...October 9, 2024 | finance.yahoo.comMillennium Management LLC Buys 110,499 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Millennium Management LLC boosted its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 57.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 303,870 sharesOctober 9, 2024 | marketbeat.com70,964 Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Acquired by Marshall Wace LLPMarshall Wace LLP bought a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 70,964 shares of the specialty pharmaceutical company's stock, valued at approximately $2,285October 5, 2024 | marketbeat.comSquarepoint Ops LLC Has $3.55 Million Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Squarepoint Ops LLC grew its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 194.5% in the second quarter, according to its most recent filing with the SEC. The fund owned 110,338 shares of the specialty pharmaceutical company's stock after acquiring an additional 72,874 sOctober 2, 2024 | marketbeat.comMaverick Capital Ltd. Acquires 30,723 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Maverick Capital Ltd. boosted its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 346.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 39,596 shares of the specialty pharmaceutical company's stockSeptember 28, 2024 | marketbeat.com Get Collegium Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Email Address How to piss off your liberal friends… and profit from it (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies. To get the full details on the fake “energy crisis” of America, watch this now COLL Media Mentions By Week COLL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COLL News Sentiment▼1.160.71▲Average Medical News Sentiment COLL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COLL Articles This Week▼44▲COLL Articles Average Week Get Collegium Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OGN News Today PTCT News Today VRNA News Today RYTM News Today MLTX News Today JANX News Today EWTX News Today XENE News Today MRUS News Today TWST News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COLL) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
